Precision Biosciences INC: directors' dealings · United States · SEC (Form 4)

About Precision Biosciences INC

Precision BioSciences, Inc. (ticker DTIL) is a U.S.-listed biotechnology company traded on NASDAQ in the United States. Headquartered in Durham, North Carolina, the company was incorporated in 2006 and built around its proprietary ARCUS® genome-editing platform, which originated from research led by its founders at Duke University. For investors, this is a classic clinical-stage biotech profile: heavy R&D spending, limited near-term commercial revenue visibility, and valuation driven primarily by clinical data, partnerships, and access to capital. Precision’s core business today is the development of in vivo gene-editing therapies for genetic and infectious diseases with significant unmet medical need. The company describes ARCUS as a compact, simple genome-editing technology with capabilities across gene cutting, insertion, and excision. While Precision historically pursued programs in immuno-oncology and allogeneic CAR-T, its recent strategic emphasis has shifted toward in vivo editing, which the company views as the most differentiated and scalable long-term opportunity. This shift is important for investors because it concentrates the narrative around a smaller number of higher-impact programs. The platform and pipeline are central to the investment case. Current attention has focused on programs in hepatitis B and selected rare genetic diseases, alongside preclinical work designed to validate ARCUS as a precise editing tool with a potentially favorable specificity profile. Precision has also highlighted scientific publications and early-stage data intended to demonstrate the breadth of ARCUS applications, including gene insertion and other complex edits. In addition, the company has pursued partnerships and licensing relationships with pharmaceutical collaborators, helping to spread development risk while preserving upside from future milestones, royalties, or program-specific economics. From a competitive standpoint, Precision operates in a crowded and fast-moving genome-editing landscape alongside larger, better-capitalized players and multiple next-generation editing platforms. Its potential edge lies in ARCUS’ small size, modularity, and the company’s focus on sophisticated edits that may be harder to achieve with some competing systems. That said, Precision remains a small-cap biotechnology company, and its outlook depends heavily on execution in clinical development, regulatory milestones, and financing conditions. As with many gene-editing names, the path to durable commercial value is still contingent on human data and eventual therapeutic adoption. Geographically, the company is concentrated in the United States, with operations centered in Durham, North Carolina. Recent corporate activity has included ongoing pipeline updates, new scientific disclosures, and capital-markets transactions to support development. For international investors, DTIL is best understood as a high-risk, high-upside biotech platform story on NASDAQ in the United States, where the key questions remain clinical translation, partner traction, and balance-sheet resilience.